Skip to main content
Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery 2/2022

Open Access 02.09.2020 | Original Article

A Comparative Study of Different Administrations of Nebulized Hyaluronic Acid After Endoscopic Endonasal Surgery for Chronic Rhinosinusitis

verfasst von: Vincenzo Abbate, Giorgio Iaconetta, Fabio Maglitto, Giovanni Improta, Antonio Romano, Paola Bonavolontà, Francesco Seidita, Luigi Califano, Giovanni Dell’Aversana Orabona

Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery | Sonderheft 2/2022

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Hyaluronic Acid (HA) plays many roles in wound healing in general, through different mechanisms. Several authors reported the effectiveness of hyaluronic acid in promoting mucosal healing and reducing discomfort for patients after endoscopic sinus surgery (ESS). Different methods for HA nasal administration have been reported. The aim of our study has been to evaluate the efficacy of the administration of nebulized HA through a nasal douche compared with its administration through a nasal spray with patients undergoing ESS for chronic rhinosinusitis. From January 2013 to January 2019 a prospective clinical trial was carried out in our hospital with 163 patients who had undergone ESS for chronic rhinosinusitis. The sample was divided into three groups according to the method of administration of HA. Our study confirm the efficacy of the administration of nebulized HA through nasal douche in post-operative care (6.5% vs 4.5%). The most relevant data regards the nasal dryness sign: the data revealed an unexpected percentage of worsening of that sign at time T3 (p = 0.049) particularly evident in the patients treated with HA through nasal douche compared to whom the nasal spray device was prescribed (4% vs 1%). Further studies are needed to identify the best means of administration of HA, which would satisfy the requirements for efficacy in terms of the results and, at the same time, patient compliance.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Hyaluronic acid (HA) is a carbohydrate, more specifically a high molecular weight mucopolysaccharide with a linear and poly repeating disaccharide structure. First discovered in 1934 (K. Meyer and J. Palmer), HA plays an important role in the formation of the extracellular matrix and in intracellular environment. The viscoelastic nature of HA, added to its biocompatibility and non-immunogenicity, has led to its use in various clinical applications in different medical fields such as dermatology, aesthetic medicine, ophthalmology, joint surgery and tissue engineering [1].
The main biological functions of HA are: the maintenance of the connective fluid tissue consistency and elastoviscosity features; tissue hydration control; water molecule carriage; and extracellular matrix proteoglycan assembly. It also has a role as a receptor in different processes such as inflammation, tumors development, mitosis and cell migration [2].
The role of HA in tissue regeneration and wound healing is well known. It has the capability to induce fibroblast stimulation and collagen deposition.
Several authors have described the use of HA with a nasal administration following endoscopic endonasal surgery (EES) and its effectiveness in improving the endonasal mucosal membrane healing [36].
Different methods for HA nasal administration have been reported: nebulized through sprays or ampoules, or topically administered with cream or nasal packing [3, 6].
These authors have confirmed the efficacy of the administration of nebulized HA through a nasal douche, compared with saline solution alone; but still now there are no comparative studies evaluating the efficacy of nebulized HA administered through nasal sprays in patients undergoing EES.
Actually, even if the intake of HA through nasal douche, is more effective, it is not equally accepted by the patient due to the higher costs and longer times required for administration compared to a pocket spray device
The aim of our study has been to evaluate the efficacy of the administration of nebulized HA through a nasal douche compared with its administration through a nasal spray with patients undergoing EES for chronic rhinosinusitis (CRS).

Methods

From January 2013 to January 2019 a prospective clinical study was carried out in the Maxillofacial Surgery Unit of the University of Naples Federico II with patients who had undergone ESS for CRS.
One hundred Sixty-three (163) patients met the following criteria and were enrolled in the study. The inclusion criteria were: CRS; and a 12-month follow-up. The exclusion criteria were: previus oncological disease; no previous surgery; and acute rhinosinusitis.
All the enrolled patients underwent endoscopic surgery (functional ESS and/or ESS) at our Department. All of them were operated on by the same surgical team and received pharmacological therapy, based on corticosteroids and antibiotics for 10 days after surgery.
After nasal packing removal, our sample was divided into three groups based on the modality of post-surgical treatment. Each patient was randomly assigned by a computerized system to one of the three groups.
The patients in group A were treated with the administration of nebulized HA through a nasal douche (Rinowash nasal douche, © Air Liquide Medical Systems, Paris, France) twice a day for 30 days; the patients in group B were treated with the administration of nebulized HA through a common nasal spray device twice a day for 30 days; and, finally, the patients in group C (the control group) were treated with a saline solution alone administered by a syringe daily for 30 days. (Table 1)
Table 1
Postoperative therapeutic protocol applied to the three groups
https://static-content.springer.com/image/art%3A10.1007%2Fs12070-020-02110-6/MediaObjects/12070_2020_2110_Tab1_HTML.png
Before undergoing surgery (T0), and at the two week follow-up (T1), four week follow-up (T2), and one year follow-up (T3) the patients from all three groups were clinically and endoscopically examined by means of two techniques: first, via nasal fibro endoscopy, which allowed different signs (nasal dryness, mucosal hyperemia, mucosal edema, secretions, crusting, traces of blood, synechia and polyps) to be studied according to a dichotomous scale (i.e. presence/absence); and secondly, a self-assessment questionnaire, the Sino-Nasal Outcome Test (SNOT-22), to report a subjective assessment of the post-operative quality of life and post-operative speed of recovery.
All the patients studied signed an informed consent approved by the Local Ethics Committee in compliance with the regulations in force.

Statistical analysis

The reported data were collected and analyzed by using Microsoft Excel 2018 to calculate medians, means and the relative standard deviations (SD) where appropriate. In addition, the Statistical Package for Social Sciences (SPSS) was used for the Shapiro–Wilk normality test and for the test of the medians with independent samples in which a p value < 0.05 was considered statistically significant. The average and median of the tabulated values were calculated in relation to the endoscopic signs, with the SD calculated by group considering the mean and median for the different parameters at the different time points (T0, T1, T2 and T3).
The null-hypothesis of the Shapiro–Wilk test was normally distributed.

Results

The samples were randomly divided into the three groups. Among the 163 patients, 99 were male and 64 were female, aged between 21 and 72 years, with an average age of 53. Sixty-five patients (39.9%) had been affected by maxillary sinusitis (monolateral or bilateral), 45 (27.6%) by ethmoid-maxillary sinusitis, 38 (23.3%) by fronto-ethmoid-maxillary sinusitis and 15 (9.2%) by pansinusitis. 97 (59.5%) had also been affected by nasal septum deviation and/or hypertrophy of the turbinates (Table 2).
Table 2
Percentage of pathology divided by location on our samples
Disease
Number of patient (total 163)
%
Maxillary sinusitis
65
39.8773
Ethmoido-maxillary sinusitis
45
27.60736
Fronto-etmoido-maxillary sinusitis
38
23.31288
Pansinusitis
15
9.202454
Nasal septum deviation and/or hypertrophy of the turbinates
97
59.5092
The analysis of the scores resulting from the SNOT-22 showed a significant improvement in the symptomatology of group A at the time T1.
At the time T2, group B achieved a progressive improvement comparable to that of group A. At the one-year follow-up (T3), the scores of the three groups overlapped within a narrow range of values (Fig. 1).
As regards the clinical signs, evaluated by means of the nasal endoscopy, the analysis of the average of the values found, showed an overall improvement in all three groups from times T1 to T3, with a trend superimposable to that observed by the SNOT-22.
In particular, group A showed an improvement in symptoms already at times T1 and T2, the incidence reducing from 43 to 36.5% and 24.5%; group B showed an overall improvement at T3 comparable to that of group A (9.38% vs 9.50%) but with a later response. Group C showed a slightly lower symptom resolution at time T3 than the other groups (12.5% vs 9.38% vs 9.5%) with a slower recovery trend (Fig. 2).
Analyzing the individual endoscopic signs, it was possible to highlight how for each symptom there was an overall improvement at time T3 with a more favorable trend in terms of resolution of the symptomatology for groups A and B.
With regard to nasal dryness, a considerable discrepancy of the percentage values at time T3 in the three groups was highlighted. In particular, the use of HA in the form of a nasal douche or nasal spray (Groups A and B, respectively) significantly reduced nasal dryness at times T1 and T2 (p = 0.049), however showing a reversal trend at time T3 greater in group A (6% vs 3%) (Fig. 3; Table 3).
Table 3
Normality test for each endoscopic sign
 
Shapiro–Wilk
Statistica
df
Sig. (p value)
Nasal dryness
Group A
0.97
4.00
0.049*
Group B
0.72
4.00
Group C
0.89
4.00
Mucosal hyperemy
Group A
0.84
4.00
0.37
Group B
0.98
4.00
Group C
0.94
4.00
Mucosal edema
Group A
0.92
4.00
0.368
Group B
0.81
4.00
Group C
0.78
4.00
Secretions
Group A
0.99
4.00
0.368
Group B
0.94
4.00
Group C
0.86
4.00
Crusting
Group A
0.93
4.00
1.00
Group B
0.95
4.00
Group C
0.94
4.00
Traces of blood
Group A
0.96
4.00
1.00
Group B
0.98
4.00
Group C
0.97
4.00
Sinechiae
Group A
0.63
4.00
0.264
Group B
0.89
4.00
Group C
0.99
4.00
Polyps
Group A
0.77
4.00
1.00
Group B
0.72
4.00
Group C
0.81
4.00
*Statistically significant p value < 0.05

Discussion

Post-operative care in endoscopic nasal and endosinusal surgery is recognized to be mandatory for an optimal healing, to limit secretions and crusting and to prevent the formation of polyps [79].
Frequent nasal washings are a very important component of post-operative care. These are generally performed with isotonic or hypertonic solutions, with a different osmolality. The most common is saline solution with 0.9% sodium chloride [10]. Recently, due to evidence of the beneficial impact of HA on mucosal healing, the tendency to use HA-based products for nasal washes has been increasing [11].
HA is a glycosaminoglycan, a linear and anionic polymer consisting of two linked sugars, glucuronic acid and N-acetylglucosamine. It tends to have a gelatinous physical state and has the capability to hydrate tissues due to its ability to bind water molecules. It is one of the main components of the extracellular matrix. Its chemical-physical features are responsible for its high biocompatibility and absorbability.
HA plays many roles in wound healing in general, through different mechanisms. The extracellular matrix rich in HA tends to stimulate cell migration by increasing both cell motility and proliferation. It also acts as a signal molecule for cell migration and induces neo-angiogenesis due to the inflammatory environments resulting from its degradation [1217].
HA plays an important role in nasal mucosal healing. When applied, it creates a gelatinous layer over the intranasal surfaces and reduces the risk of synechia, providing an adequate mucosal hydration and vascularization. Furthermore, Cassano et al. [18] reported that in patients undergoing EES, HA promoted both mucociliary clearance and mucosal regeneration as a consequence of a faster recovery of the impaired ciliated cells. The action of HA on the ciliary motility may be explained by the fact that the breaking of each molecule, initiated by free radicals and hyaluronidase during inflammation, into active fragments with a low molecular weight increases the frequency of the ciliary beat. This action is mediated by the increase in the concentration of calcium ions and the interactions between the HA fragments, HA-mediated motility receptors and receptors of origin are present on the cilia [19]. Thus, HA limits the incidence of rhinorrhea and nasal obstruction, and reduces the number of secretions on endoscopic evaluation due to improvements in the mucociliary clearance [20].
Several Authors [4, 5] have reported the beneficial healing effect of the administration of nebulized HA on the nasal mucosa, in comparison with the use of saline solution alone, after EES [21]. Based on our clinical experience, nasal douche requires a high level of patient compliance due to the time required for the preparation of the therapy and the need for an electric nebulization device. For this reason, we have evaluated the efficacy of the administration of nebulized HA through a nasal spray, comparing it with that achieved by using a nasal douche. These nasal sprays are pocket-sized, ready-to-use and, therefore, are generally tolerated better by the patient.
Our results have confirmed the efficacy of the HA administration through a nasal douche, especially in terms of the speed of healing at time T1. As reported in our results, we have revealed a rapid improvement in the symptoms detected during the clinical examination in the group A, compared to the group B where the administration was performed through a nasal spray, with a percentage of improvement of about 6.5% at T1 and 4.5% at T2.
Nevertheless, at times T2 and T3 the difference between the two groups (A and B) is greatly reduced (Figs. 1, 2). The most relevant data regards the nasal dryness sign: The data show a statistically significant improvement of the sign (p = 0.049) in the groups A and B at times T1 and T2 with an unexpected percentage of worsening of the sign at time T3 particularly evident in group A compared to B (4% vs 1%).
This evidence may be linked to a lower long-term tolerability in the administration of HA through the nasal douche compared to a more manageable long-term administration using a nasal spray.
In our case series, even though it is better tolerated, the administration through a spray has proved less effective in improving the post-operative symptomatology. Casale et al. [2224] described a new nasal device for the administration of nebulized HA. The results of this prospective study suggest the administration of nebulized HA through this new device (Spray-sol) as a supportive treatment for a faster improvement of nasal respiration, also minimizing patient discomfort and promoting nasal mucosa healing in post-operative ESS for CRS.
The results of our study confirm the efficacy of nebulized HA in post-operative treatment. In order to reduce any complications and to obtain a faster nasal mucosa healing nebulized HA is recommended. We can observe from our study a better patient compliance when a pocket device is used.
Further studies are needed to identify the best means of HA administration, which would satisfy the requirements for an efficacy in terms of the results and, at the same time, patient compliance.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

Die Chirurgie

Print-Titel

Das Abo mit mehr Tiefe

Mit der Zeitschrift Die Chirurgie erhalten Sie zusätzlich Online-Zugriff auf weitere 43 chirurgische Fachzeitschriften, CME-Fortbildungen, Webinare, Vorbereitungskursen zur Facharztprüfung und die digitale Enzyklopädie e.Medpedia.

e.Med Interdisziplinär

Kombi-Abonnement

Jetzt e.Med zum Sonderpreis bestellen!

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt bestellen und 100 € sparen!

e.Dent – Das Online-Abo der Zahnmedizin

Online-Abonnement

Mit e.Dent erhalten Sie Zugang zu allen zahnmedizinischen Fortbildungen und unseren zahnmedizinischen und ausgesuchten medizinischen Zeitschriften.

Weitere Produktempfehlungen anzeigen
Literatur
1.
Zurück zum Zitat Price RD, Berry MG, Navsaria HA (2007) Hyaluronic acid: the scientific and clinical evidence. J Plast Reconstr Aesthet Surg 60:1110–1119CrossRefPubMed Price RD, Berry MG, Navsaria HA (2007) Hyaluronic acid: the scientific and clinical evidence. J Plast Reconstr Aesthet Surg 60:1110–1119CrossRefPubMed
2.
Zurück zum Zitat Necas L Bartosikova, Brauner P et al (2008) Hyaluronic acid (hyaluronan): a review. Veterinarnimedicina 53:397–411 Necas L Bartosikova, Brauner P et al (2008) Hyaluronic acid (hyaluronan): a review. Veterinarnimedicina 53:397–411
3.
Zurück zum Zitat Chang C, Hong SM, Cho JH et al (2014) A randomized, multi-center, single blind, active-controlled, matched pairs clinical study to evaluate prevention of adhesion formation and safety of hyfence in patients after endoscopic sinus surgery. Clin Exp Otorhinolaryngol 7:30–35CrossRefPubMedPubMedCentral Chang C, Hong SM, Cho JH et al (2014) A randomized, multi-center, single blind, active-controlled, matched pairs clinical study to evaluate prevention of adhesion formation and safety of hyfence in patients after endoscopic sinus surgery. Clin Exp Otorhinolaryngol 7:30–35CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Macchi A, Terranova P, Digilio E et al (2013) Hyaluronan plus saline nasal washes in the treatment of rhino-sinusal symptoms in patients undergoing functional endoscopic sinus surgery for rhino-sinusal remodeling. Int J ImmunopatholPharmacol 26:137–145CrossRef Macchi A, Terranova P, Digilio E et al (2013) Hyaluronan plus saline nasal washes in the treatment of rhino-sinusal symptoms in patients undergoing functional endoscopic sinus surgery for rhino-sinusal remodeling. Int J ImmunopatholPharmacol 26:137–145CrossRef
5.
Zurück zum Zitat Cantone E, Castagna G, Sicignano S et al (2014) Impact of intranasal sodium hyaluronate on the short-term quality of life of patients undergoing functional endoscopic sinus surgery for chronic rhinosinusitis. Int Forum Allergy Rhinol 4:484–487CrossRefPubMed Cantone E, Castagna G, Sicignano S et al (2014) Impact of intranasal sodium hyaluronate on the short-term quality of life of patients undergoing functional endoscopic sinus surgery for chronic rhinosinusitis. Int Forum Allergy Rhinol 4:484–487CrossRefPubMed
6.
Zurück zum Zitat Miller RS, Steward DL, Tami TA et al (2003) The clinical effects of hyaluronic acid ester nasal dressing (Merogel) on intranasal wound healing after functional endoscopic sinus surgery. Otolaryngol Head Neck Surg 128:862–869PubMed Miller RS, Steward DL, Tami TA et al (2003) The clinical effects of hyaluronic acid ester nasal dressing (Merogel) on intranasal wound healing after functional endoscopic sinus surgery. Otolaryngol Head Neck Surg 128:862–869PubMed
7.
Zurück zum Zitat Aouad RK, Chiu AG (2011) State of the art treatment of nasal polyposis. Am J Rhinol Allergy 25:291–298CrossRefPubMed Aouad RK, Chiu AG (2011) State of the art treatment of nasal polyposis. Am J Rhinol Allergy 25:291–298CrossRefPubMed
8.
Zurück zum Zitat Romano A, Orabona GD, Salzano G et al (2015) Comparative study between partial inferior turbinotomy and microdebrider-assisted inferior turbinoplasty. J Craniofac Surg 26:235–238CrossRef Romano A, Orabona GD, Salzano G et al (2015) Comparative study between partial inferior turbinotomy and microdebrider-assisted inferior turbinoplasty. J Craniofac Surg 26:235–238CrossRef
9.
Zurück zum Zitat Dell’Aversana Orabona G, Romano A, Abbate V et al (2018) Effectiveness of endoscopic septoplasty in different types of nasal septal deformities: our experience with NOSE evaluation. Acta Otorhinolaryngol Ital 38:323–330CrossRefPubMedPubMedCentral Dell’Aversana Orabona G, Romano A, Abbate V et al (2018) Effectiveness of endoscopic septoplasty in different types of nasal septal deformities: our experience with NOSE evaluation. Acta Otorhinolaryngol Ital 38:323–330CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Rudmik L, Soler ZM, Orlandi RR et al (2011) Early postoperative care following endoscopic sinus surgery: an evidence-based review with recommendations. Int Forum Allergy Rhinol 1:417–430CrossRefPubMed Rudmik L, Soler ZM, Orlandi RR et al (2011) Early postoperative care following endoscopic sinus surgery: an evidence-based review with recommendations. Int Forum Allergy Rhinol 1:417–430CrossRefPubMed
11.
Zurück zum Zitat Testa D, Guerra G, Conzo G et al (2013) Glottic-Subglotticadenoidcystic carcinoma. A case report and review of the literature. BMC Surg 13:48CrossRef Testa D, Guerra G, Conzo G et al (2013) Glottic-Subglotticadenoidcystic carcinoma. A case report and review of the literature. BMC Surg 13:48CrossRef
12.
Zurück zum Zitat Collins MN, Birkinshaw C (2008) Physical properties of crosslinked hyaluronic acid hydrogels. J Mater Sci Mater Med 19:3335–3343CrossRefPubMed Collins MN, Birkinshaw C (2008) Physical properties of crosslinked hyaluronic acid hydrogels. J Mater Sci Mater Med 19:3335–3343CrossRefPubMed
13.
Zurück zum Zitat Lapcík L Jr, Lapcík L, De Smedt S et al (1998) Hyaluronan: preparation, structure, properties, and applications. Chem Rev 98:2663–2684CrossRefPubMed Lapcík L Jr, Lapcík L, De Smedt S et al (1998) Hyaluronan: preparation, structure, properties, and applications. Chem Rev 98:2663–2684CrossRefPubMed
14.
Zurück zum Zitat Chen WY, Abatangelo G (1999) Functions of hyaluronan in wound repair. Wound Repair Regen 7:79–89CrossRefPubMed Chen WY, Abatangelo G (1999) Functions of hyaluronan in wound repair. Wound Repair Regen 7:79–89CrossRefPubMed
15.
Zurück zum Zitat Dell’Aversana Orabona G, Abbate V, Maglitto F et al (2018) Low cost, self-made CAD/CAM-guiding system for mandibular reconstruction. Surg Oncol 27:200–207CrossRefPubMed Dell’Aversana Orabona G, Abbate V, Maglitto F et al (2018) Low cost, self-made CAD/CAM-guiding system for mandibular reconstruction. Surg Oncol 27:200–207CrossRefPubMed
16.
Zurück zum Zitat Turley EA, Nobel PW (2002) Signalling properties of hyaluronan receptors. J Biol Chem 277:4589–4592CrossRefPubMed Turley EA, Nobel PW (2002) Signalling properties of hyaluronan receptors. J Biol Chem 277:4589–4592CrossRefPubMed
17.
Zurück zum Zitat Palumbo FS, Pitarresi G, Mandracchia D et al (2006) New graft copolymers of hyaluronic acid and polylactic acid: synthesis and characterization. Carbohydr Polym 66:379–385CrossRef Palumbo FS, Pitarresi G, Mandracchia D et al (2006) New graft copolymers of hyaluronic acid and polylactic acid: synthesis and characterization. Carbohydr Polym 66:379–385CrossRef
18.
Zurück zum Zitat Cassano M, Russo GM, Granieri C et al (2016) Cytofunctional changes in nasal ciliated cells in patients treated with hyaluronate after nasal surgery. Am J Rhinol Allergy 30:83–88CrossRefPubMed Cassano M, Russo GM, Granieri C et al (2016) Cytofunctional changes in nasal ciliated cells in patients treated with hyaluronate after nasal surgery. Am J Rhinol Allergy 30:83–88CrossRefPubMed
19.
Zurück zum Zitat Manzanares D, Monzon ME, Savani RC et al (2007) Apical oxidative hyaluronan degradation stimulates airway ciliary beating via RHAMM and RON. Am J Respir Cell Mol Biol 37:160–168CrossRefPubMedPubMedCentral Manzanares D, Monzon ME, Savani RC et al (2007) Apical oxidative hyaluronan degradation stimulates airway ciliary beating via RHAMM and RON. Am J Respir Cell Mol Biol 37:160–168CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Gelardi M, Guglielmi AV, De Candia N et al (2013) Effect of sodium hyaluronate on mucociliary clearance after functional endoscopic sinus surgery. Eur Ann Allergy Clin Immunol 45:103–108PubMed Gelardi M, Guglielmi AV, De Candia N et al (2013) Effect of sodium hyaluronate on mucociliary clearance after functional endoscopic sinus surgery. Eur Ann Allergy Clin Immunol 45:103–108PubMed
21.
Zurück zum Zitat Levine HL (1990) Functional endoscopic sinus surgery: evaluation, surgery, and follow-up of 250 patients. Laryngoscope 100:79–84CrossRefPubMed Levine HL (1990) Functional endoscopic sinus surgery: evaluation, surgery, and follow-up of 250 patients. Laryngoscope 100:79–84CrossRefPubMed
22.
Zurück zum Zitat Casale M, Pace A, Moffa A et al (2017) Post-operative nebulized sodium hyaluronate versus spray after functional endoscopic sinus surgery for chronic rhinosinusitis. J Biol Regul Homeost Agents 27:31 Casale M, Pace A, Moffa A et al (2017) Post-operative nebulized sodium hyaluronate versus spray after functional endoscopic sinus surgery for chronic rhinosinusitis. J Biol Regul Homeost Agents 27:31
23.
Zurück zum Zitat Moffa A, Costantino A, Rinaldi V et al (2019) Nasal delivery devices: a comparative study on cadaver model. Biomed Res Int 10:1–6CrossRef Moffa A, Costantino A, Rinaldi V et al (2019) Nasal delivery devices: a comparative study on cadaver model. Biomed Res Int 10:1–6CrossRef
24.
Zurück zum Zitat Valentine R, Athanasiadis T, Thwin M et al (2008) A prospective controlled trial of pulsed nasal nebulizer in maximally dissected cadavers. Am J Rhinol 22:390–394CrossRefPubMed Valentine R, Athanasiadis T, Thwin M et al (2008) A prospective controlled trial of pulsed nasal nebulizer in maximally dissected cadavers. Am J Rhinol 22:390–394CrossRefPubMed
Metadaten
Titel
A Comparative Study of Different Administrations of Nebulized Hyaluronic Acid After Endoscopic Endonasal Surgery for Chronic Rhinosinusitis
verfasst von
Vincenzo Abbate
Giorgio Iaconetta
Fabio Maglitto
Giovanni Improta
Antonio Romano
Paola Bonavolontà
Francesco Seidita
Luigi Califano
Giovanni Dell’Aversana Orabona
Publikationsdatum
02.09.2020
Verlag
Springer India
Erschienen in
Indian Journal of Otolaryngology and Head & Neck Surgery / Ausgabe Sonderheft 2/2022
Print ISSN: 2231-3796
Elektronische ISSN: 0973-7707
DOI
https://doi.org/10.1007/s12070-020-02110-6

Weitere Artikel der Sonderheft 2/2022

Indian Journal of Otolaryngology and Head & Neck Surgery 2/2022 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.